Portal de Periódicos da CAPES

A RIPK1-specific PROTAC degrader achieves potent antitumor activity by enhancing immunogenic cell death

2024; Cell Press; Volume: 57; Issue: 7 Linguagem: Inglês

10.1016/j.immuni.2024.04.025

1097-4180

Jonathan Mannion, Valentina Gifford, Benjamin R. Bellenie, Winnie Fernando, Laura Ramos Garcia, Rebecca Wilson, Sidonie Wicky John, Savita Udainiya, Emmanuel C. Patin, Crescens Tiu, Ángel Smith, Maria Goicoechea, Andrew Craxton, Nathalia Moraes de Vasconcelos, Naomi Guppy, Kwai-Ming J. Cheung, Nicholas J. Cundy, Olivier A. Pierrat, Alfie Brennan, Theodoros I. Roumeliotis, Graeme Benstead-Hume, John Alexander, Gareth Muirhead, Scott Layzell, Wenxin Lyu, Victoria Roulstone, Mark Allen, Holly Baldock, Arnaud J. Legrand, Florian Gabel, Natalia Serrano-Aparicio, Chris Starling, Hongyan Guo, Jason W. Upton, Mads Gyrd‐Hansen, Marion MacFarlane, Benedict Seddon, Florence I. Raynaud, Ioannis Roxanis, Kevin J. Harrington, Syed Haider, Jyoti S. Choudhary, Swen Hoelder, Tencho Tenev, Pascal Meier,

Ubiquitin and proteasome pathways

Receptor-interacting serine/threonine-protein kinase 1 (RIPK1) functions as a critical stress sentinel that coordinates cell survival, inflammation, and immunogenic cell death (ICD). Although the catalytic function of RIPK1 is required to trigger cell death, its non-catalytic scaffold function mediates strong pro-survival signaling. Accordingly, cancer cells can hijack RIPK1 to block necroptosis and evade immune detection. We generated a small-molecule proteolysis-targeting chimera (PROTAC) that selectively degraded human and murine RIPK1. PROTAC-mediated depletion of RIPK1 deregulated TNFR1 and TLR3/4 signaling hubs, accentuating the output of NF-κB, MAPK, and IFN signaling. Additionally, RIPK1 degradation simultaneously promoted RIPK3 activation and necroptosis induction. We further demonstrated that RIPK1 degradation enhanced the immunostimulatory effects of radio- and immunotherapy by sensitizing cancer cells to treatment-induced TNF and interferons. This promoted ICD, antitumor immunity, and durable treatment responses. Consequently, targeting RIPK1 by PROTACs emerges as a promising approach to overcome radio- or immunotherapy resistance and enhance anticancer therapies.